Dora Valent
YOU?
Author Swipe
View article: Serum Neurofilament Light and Clinical Biomarkers for Disease Staging in Huntington's Disease
Serum Neurofilament Light and Clinical Biomarkers for Disease Staging in Huntington's Disease Open
Recently, the Huntington's Disease (HD) Integrated Staging System (HD-ISS) was developed as a new framework to standardize clinical research for HD.1 Nevertheless, HD patients can show variable performance in certain tests at a particular …
View article: Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson’s Disease
Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson’s Disease Open
Background: Sarcopenia is characterized by a progressive loss of muscle mass, strength, and function resulting in adverse health outcomes. Current assessment strategies are bothersome and means to simplify the diagnosis are an unmet medica…
View article: Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease Open
Background: Early identification of Parkinson’s disease (PD) patients at risk for becoming functionally dependent is important for patient counseling. Several models describing the relationship between predictors and outcome have been repo…
View article: Different assessment tools to detect sarcopenia in patients with Parkinson's disease
Different assessment tools to detect sarcopenia in patients with Parkinson's disease Open
Introduction Sarcopenia and Parkinson's disease are closely related diseases of the elderly population leading to progressive disability and nursing-dependent care. Objective The aim of this study was to estimate the prevalence of sarcopen…
View article: Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study Open
The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoi…
View article: Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone Open
Objective The objective of this study was to assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in Parkinson's disease (PD). Methods This was a phase II placeb…
View article: Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington’s Disease: A Pilot Study
Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington’s Disease: A Pilot Study Open
Objective: The aim of this pilot study was to investigate change of olfactory functions in Huntington’s disease (HD). Background: HD is a neurodegenerative disease characterized by motor, cognitive, and behavioral abnormalities. There are …
View article: Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study) Open
Although open-label observations report a positive effect of cannabinoids on non-motor symptoms (NMS) in Parkinson's disease (PD) patients, these effects remain to be investigated in a controlled trial for a broader use in NMS in PD patien…